Entero Healthcare Solutions quarterly results

Q1 FY27 · Apr–Jun 2026

₹ crore	Q1 FY27	Q1 FY26	Change
Revenue	1,940	1,404	+38.2%
EBITDA	97.0	50.1	+93.7%
EBITDA margin	5.0%	3.6%	+1.4 pts
Profit before tax	67.1	36.4	+84.6%
Net profit	52.1	30.2	+72.2%
EPS	₹8.77	₹6.39	+37.2%

Every quarter

₹ crore except per share

Tap a line for its trend	Q1 FY27Jun 2026	Q4 FY26Mar 2026	Q3 FY26Dec 2025	Q2 FY26Sep 2025	Q1 FY26Jun 2025	Q4 FY25Mar 2025	Q3 FY25Dec 2024	Q2 FY25Sep 2024	Q1 FY25Jun 2024	Q4 FY24Mar 2024	Q3 FY24Dec 2023

Expenses
	1,940	1,910	1,707	1,571	1,404	1,339	1,359	1,301	1,097	1,034	993
	3.0	4.0	4.6	4.8	5.8	7.3	7.5	11.3	13.4	9.1	1.8
	1,944	1,914	1,711	1,576	1,410	1,346	1,366	1,312	1,110	1,043	994
	1,725	1,691	1,526	1,398	1,299	1,205	1,284	1,198	1,070	956	912
	−6.2	11.5	7.5	11.8	−34.8	3.4	−57.9	−19.8	−72.6	−14.5	−9.3
	69.4	64.8	64.0	59.2	57.6	52.0	53.4	50.1	43.6	37.9	39.9
	20.6	17.3	14.0	12.4	10.7	10.5	10.0	11.5	9.7	17.3	16.1
	12.3	14.8	9.8	9.8	8.9	8.5	8.1	7.5	6.6	7.1	6.0
	55.0	56.6	40.8	39.5	31.9	29.8	30.0	29.7	26.2	25.8	21.7
	1,876	1,856	1,663	1,531	1,373	1,309	1,327	1,277	1,083	1,030	986
	97.0	86.0	67.8	62.1	50.1	48.9	50.0	42.4	30.2	28.9	28.6
	84.7	71.3	58.0	52.2	41.2	40.4	41.9	35.0	23.6	21.7	22.6
Profit
	67.1	57.9	48.6	44.6	36.4	37.2	39.4	34.8	27.3	13.6	8.3
	0.0	0.0	−8.2	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
	67.1	57.9	40.4	44.6	36.4	37.2	39.4	34.8	27.3	13.6	8.3
	17.7	20.4	18.3	12.7	8.1	3.9	8.3	7.3	6.2	5.1	1.6
	−2.6	−7.6	−11.8	−4.6	−2.0	1.9	1.7	1.5	0.6	−12.7	−0.2
	15.1	12.8	6.5	8.0	6.1	5.8	10.0	8.7	6.8	−7.6	1.3
	52.1	45.1	33.9	36.6	30.2	31.4	29.4	26.0	20.5	21.2	7.0
	52.1	45.1	33.9	36.6	30.2	31.4	29.4	26.0	20.5	21.2	7.0
	−0.1	−0.3	−0.0	−0.4	0.1	0.6	−0.0	−0.0	−0.0	−0.2	−0.1
	51.9	44.8	33.9	36.2	30.4	32.0	29.4	26.0	20.5	21.0	6.9
	38.2	28.0	27.6	31.6	27.8	25.7	25.4	23.6	—	21.0	6.8
	13.9	17.1	6.2	5.0	2.4	5.7	4.0	2.4	—	0.2	0.2
Per share
	₹8.77	₹6.44	₹6.35	₹7.26	₹6.39	₹5.91	₹5.85	₹5.43	₹4.62	₹5.73	₹1.91
	₹8.76	₹6.43	₹6.34	₹7.25	₹6.38	₹5.90	₹5.84	₹5.42	₹4.62	₹5.73	₹1.91
Other comprehensive income — detail
	−0.1	−0.3	−0.0	−0.4	0.1	0.6	—	—	—	—	—
	−0.2	−0.4	−0.0	−0.6	0.2	0.8	−0.0	−0.0	−0.0	−0.2	−0.1
	−0.0	−0.1	−0.0	−0.1	0.0	0.2	—	—	—	—	—
	—	—	—	—	—	—	−0.0	−0.0	−0.0	−0.0	0.0
	38.0	27.7	27.6	31.2	27.9	26.1	25.4	23.6	20.0	20.8	6.7
	13.9	17.1	6.2	5.0	2.5	5.9	4.0	2.4	0.5	0.2	0.2
Per share — as-filed variants
	₹8.77	₹6.44	₹6.35	₹7.26	₹6.39	₹5.91	₹5.85	₹5.43	₹4.62	₹5.73	₹1.91
	₹8.76	₹6.43	₹6.34	₹7.25	₹6.38	₹5.90	₹5.84	₹5.42	₹4.62	₹5.73	₹1.91
Derived — gross profit (revenue − materials − purchases − Δ inventories)
	221	207	173	161	140	131	133	122	100.0	92.6	90.2
	11.4%	10.9%	10.1%	10.2%	9.9%	9.8%	9.8%	9.4%	9.1%	9.0%	9.1%
Adjusted (ex-exceptional items) — derived
	67.1	57.9	48.6	44.6	36.4	37.2	39.4	34.8	27.3	13.6	8.3
	0.0	0.0	−8.2	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
	52.1	45.1	40.7	36.6	30.2	31.4	29.4	26.0	20.5	21.2	7.0
	₹8.77	₹6.44	₹7.64	₹7.26	₹6.39	₹5.91	₹5.85	₹5.43	₹4.62	₹5.73	₹1.91

Open the chart

From the company's filings with NSE and BSE (Ind-AS), consolidated. For information only, not investment advice.

alphave

ENTERO₹1,599.00

Entero Healthcare Solutions Ltd.

· Consumer Services

Annual Quarterly₹ CrorePeersMEDPLUS EMIL CRIZAC GPPL CMSINFO HEMIPROP BLACKBUCK INOXGREENMcap ₹6,957 Cr

View

In ₹ Crore except Per Share 3 Months Ending	Q3 FY24 31/12/2023	Q4 FY24 31/03/2024	Q1 FY25 30/06/2024	Q2 FY25 30/09/2024	Q3 FY25 31/12/2024	Q4 FY25 31/03/2025	Q1 FY26 30/06/2025	Q2 FY26 30/09/2025	Q3 FY26 31/12/2025	Q4 FY26 31/03/2026	Q1 FY27 30/06/2026
Revenue from Operations	992.6	1,034.2	1,097.0	1,300.7	1,359.0	1,339.1	1,403.8	1,570.9	1,706.5	1,909.9	1,940.5
Other Income	1.8	9.1	13.4	11.3	7.5	7.3	5.8	4.8	4.6	4.0	3.0
Total Income	994.4	1,043.3	1,110.5	1,312.0	1,366.5	1,346.3	1,409.6	1,575.7	1,711.1	1,913.9	1,943.5
Expenses
+ Purchases of Stock-in-Trade	911.7	956.0	1,069.7	1,198.4	1,283.5	1,204.9	1,299.0	1,398.3	1,526.5	1,691.0	1,725.3
+ Changes in Inventories	-9.3	-14.5	-72.6	-19.8	-57.9	3.4	-34.8	11.8	7.5	11.5	-6.2
+ Employee Benefit Expense	39.9	37.9	43.6	50.1	53.4	52.0	57.6	59.2	64.0	64.8	69.4
+ Finance Costs	16.1	17.3	9.7	11.5	10.0	10.5	10.7	12.4	14.0	17.3	20.6
+ Depreciation & Amortisation	6.0	7.1	6.6	7.5	8.1	8.5	8.9	9.8	9.8	14.8	12.3
+ Other Expenses	21.7	25.8	26.2	29.7	30.0	29.8	31.9	39.5	40.8	56.6	55.0
Total Expenses	986.1	1,029.8	1,083.2	1,277.2	1,327.1	1,309.1	1,373.3	1,531.1	1,662.6	1,856.0	1,876.4
EBITDA	28.6	28.9	30.2	42.4	50.0	48.9	50.1	62.1	67.8	86.0	97.0
EBIT	22.6	21.7	23.6	35.0	41.9	40.4	41.2	52.2	58.0	71.3	84.7
Profit
PBT before Exceptional Items	8.3	13.6	27.3	34.8	39.4	37.2	36.4	44.6	48.6	57.9	67.1
+ Exceptional Items	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	-8.2	0.0	0.0
Pretax Income	8.3	13.6	27.3	34.8	39.4	37.2	36.4	44.6	40.4	57.9	67.1
+ Current Tax	1.6	5.1	6.2	7.3	8.3	3.9	8.1	12.7	18.3	20.4	17.7
+ Deferred Tax	-0.2	-12.7	0.6	1.5	1.7	1.9	-2.0	-4.6	-11.8	-7.6	-2.6
Tax Expense	1.3	-7.6	6.8	8.7	10.0	5.8	6.1	8.0	6.5	12.8	15.1
Net Income	7.0	21.2	20.5	26.0	29.4	31.4	30.2	36.6	33.9	45.1	52.1
+ Net Income — Continuing Ops	7.0	21.2	20.5	26.0	29.4	31.4	30.2	36.6	33.9	45.1	52.1
+ Other Comprehensive Income	-0.1	-0.2	-0.0	-0.0	-0.0	0.6	0.1	-0.4	-0.0	-0.3	-0.1
Total Comprehensive Income	6.9	21.0	20.5	26.0	29.4	32.0	30.4	36.2	33.9	44.8	51.9
Net Income to Common	6.8	21.0	—	23.6	25.4	25.7	27.8	31.6	27.6	28.0	38.2
Minority Interest	0.2	0.2	—	2.4	4.0	5.7	2.4	5.0	6.2	17.1	13.9
Per Share
Basic EPS	1.91	5.73	4.62	5.43	5.85	5.91	6.39	7.26	6.35	6.44	8.77
Diluted EPS	1.91	5.73	4.62	5.42	5.84	5.90	6.38	7.25	6.34	6.43	8.76
Other Comprehensive Income — detail
+ Other Comprehensive Income	—	—	—	—	—	0.6	0.1	-0.4	-0.0	-0.3	-0.1
+ Items NOT to be Reclassified to P&L	-0.1	-0.2	-0.0	-0.0	-0.0	0.8	0.2	-0.6	-0.0	-0.4	-0.2
+ Tax on Items NOT to be Reclassified	—	—	—	—	—	0.2	0.0	-0.1	-0.0	-0.1	-0.0
+ Tax on Items NOT to be Reclassified — alt tag	0.0	-0.0	-0.0	-0.0	-0.0	—	—	—	—	—	—
Comprehensive Income — Owners of Parent	6.7	20.8	20.0	23.6	25.4	26.1	27.9	31.2	27.6	27.7	38.0
Comprehensive Income — Non-controlling Interests	0.2	0.2	0.5	2.4	4.0	5.9	2.5	5.0	6.2	17.1	13.9
Per Share — as-filed variants
Basic EPS — Continuing Operations	1.91	5.73	4.62	5.43	5.85	5.91	6.39	7.26	6.35	6.44	8.77
Diluted EPS — Continuing Operations	1.91	5.73	4.62	5.42	5.84	5.90	6.38	7.25	6.34	6.43	8.76
Derived — Gross Profit (Revenue − Materials − Purchases − Δ Inventories)
Gross Profit	90.2	92.6	100.0	122.2	133.4	130.8	139.6	160.8	172.6	207.4	221.4
Gross Margin %	9.09	8.95	9.11	9.39	9.82	9.77	9.94	10.24	10.11	10.86	11.41
Adjusted (ex-Exceptional Items) — derived
Pretax Income (Adjusted, as filed)	8.3	13.6	27.3	34.8	39.4	37.2	36.4	44.6	48.6	57.9	67.1
− Exceptional Items (reconciliation)	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	-8.2	0.0	0.0
Net Income Adj (tax-effected)	7.0	21.2	20.5	26.0	29.4	31.4	30.2	36.6	40.7	45.1	52.1
EPS Adj	1.91	5.73	4.62	5.43	5.85	5.91	6.39	7.26	7.64	6.44	8.77
Other Filed Concepts — mapped but not yet placed in the schedule
Face Value	10.00	10.00	10.00	10.00	10.00	10.00	10.00	10.00	10.00	10.00	10.00
Filed Debt Equity	1.00	—	—	—	—	—	—	—	—	—	—
Paid Up Equity Capital	16.1	43.5	43.5	43.5	43.5	43.5	43.5	43.5	43.5	43.5	43.5

As filed, sign as filed — read the label, not the sign. A line appears only when the company tagged that concept in at least one period shown, so depth follows the filer: pre-Ind-AS, insurance and NBFC blocks stay hidden unless they were actually reported. Alternate tags for the same idea (e.g. two spellings of a deferred-tax element) are kept as separate lines rather than merged, because merging them would be a guess. Ratios, per-share figures and counts render as raw numbers, not ₹ Crore. No consensus estimates → no Est columns. Click any row to chart it.

« ‹ › »Latest: Q1 FY27 · ConsolidatedFA Financial Analysis · alphave

Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreement — XBRL cross-verified ✓ 95%.

Entero Healthcare Solutions Q2 FY27 results date

Entero Healthcare Solutions (NSE: ENTERO) will announce its Q2 FY27 results (July–September 2026) on Wednesday, 4 November 2026, according to the board-meeting notice it filed on 22 October 2026. Its latest results are for Q1 FY27 (April–June 2026). Consolidated net profit attributable to shareholders was ₹38.2 crore, up 37.3% from ₹27.8 crore in Q1 FY26 and up 36.2% from ₹28 crore in Q4 FY26. Revenue from operations was ₹1,940 crore, up 38.2% year on year and up 1.6% from the previous quarter.

Board-meeting notice filed: 22 October 2026
Q2 FY26 results (a year earlier): 12 November 2025
Q1 FY27 results (the latest): 7 August 2026

Latest results: Q1 FY27 (Apr–Jun 2026) · consolidated

Q2 FY27 results date: 4 November 2026Wednesday · notice filed 22 Oct
Q1 FY27 net profit: ₹38.2 Cr+37.3% vs Q1 FY26+36.2% vs Q4 FY26
Q1 FY27 revenue: ₹1,940 Cr+38.2% vs Q1 FY26+1.6% vs Q4 FY26
Q1 FY27 operating margin: 4.4%+1.4 pts vs Q1 FY26+0.6 pts vs Q4 FY26
Q2 FY26 net profit (a year earlier): ₹31.6 CrRevenue ₹1,571 Cr
Q1 FY27 EPS (basic): ₹8.77

Questions

When will Entero Healthcare Solutions announce its Q2 FY27 results?

On 4 November 2026, the date of the board meeting called to approve them (notice filed with the exchanges on 22 October 2026). Last year it reported Q2 FY26 on 12 November 2025.

What will Entero Healthcare Solutions' Q2 FY27 results be compared with?

With the same quarter a year earlier, Q2 FY26 (July–September 2025), when consolidated net profit attributable to shareholders was ₹31.6 crore and revenue from operations ₹1,571 crore. The latest quarter, Q1 FY27, had a net profit of ₹38.2 crore and revenue of ₹1,940 crore.

What were Entero Healthcare Solutions' Q1 FY27 results?

Consolidated net profit attributable to shareholders was ₹38.2 crore, up 37.3% from ₹27.8 crore in Q1 FY26 and up 36.2% from ₹28 crore in Q4 FY26. Revenue from operations was ₹1,940 crore, up 38.2% year on year and up 1.6% from the previous quarter.

How has Entero Healthcare Solutions' profit changed over the last four quarters?

Net profit attributable to shareholders by quarter: ₹31.6 crore in Q2 FY26, ₹27.6 crore in Q3 FY26, ₹28 crore in Q4 FY26 and ₹38.2 crore in Q1 FY27. That is ₹125 crore over the four quarters, up 22.3% from ₹103 crore in the four quarters before. Revenue from operations: ₹1,571 crore, ₹1,707 crore, ₹1,910 crore and ₹1,940 crore.

What was Entero Healthcare Solutions' net profit in FY26?

Consolidated net profit attributable to shareholders was ₹115 crore in FY26 (April 2025–March 2026), up 21.3% from ₹94.8 crore in FY25. It was ₹39.1 crore in FY24.

What was Entero Healthcare Solutions' revenue in FY26?

Revenue from operations was ₹6,591 crore in FY26 (April 2025–March 2026), up 29.3% from ₹5,096 crore in FY25. It was ₹3,922 crore in FY24.

Where do these Entero Healthcare Solutions figures come from?

From Entero Healthcare Solutions' own consolidated results filings to NSE, in ₹ crore as filed; the date from its board-meeting notices.

Consolidated figures from the company's filings to NSE. Every company's results dates this season are in the Q2 FY27 results calendar, part of Alpha Plus.